Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective by Maiara Marx Luz Fiusa et al.
Fiusa et al. BMC Medicine  (2015) 13:105 
DOI 10.1186/s12916-015-0327-2OPINION Open AccessCauses and consequences of coagulation activation
in sepsis: an evolutionary medicine perspective
Maiara Marx Luz Fiusa1, Marco Antonio Carvalho-Filho1, Joyce M Annichino-Bizzacchi1,2 and Erich V De Paula1,2*Abstract
Background: Coagulation and innate immunity have been linked together for at least 450 million years of evolution.
Sepsis, one of the world’s leading causes of death, is probably the condition in which this evolutionary link is more
evident. However, the biological and the clinical relevance of this association have only recently gained the attention
of the scientific community.
Discussion: During sepsis, the host response to a pathogen is invariably associated with coagulation activation.
For several years, coagulation activation has been solely regarded as a mechanism of tissue damage, a concept that
led to several clinical trials of anticoagulant agents for sepsis. More recently, this paradigm has been challenged by the
failure of these clinical trials, and by a growing bulk of evidence supporting the concept that coagulation activation is
beneficial for pathogen clearance. In this article we discuss recent basic and clinical data that point to a more balanced
view of the detrimental and beneficial consequences of coagulation activation in sepsis.
Summary: Reappraisal of the association between coagulation and immune activation from an evolutionary medicine
perspective offers a unique opportunity to gain new insights about the pathogenesis of sepsis, paving the way to more
successful approaches in both basic and clinical research in this field.Background
Sepsis has been recently defined as a “life threatening
condition that arises when a body’s response to an infec-
tion injures its own tissues and organs” [1]. The last de-
cades have witnessed continuous improvements in our
understanding of the pathogenesis of this condition.
Nonetheless, sepsis is still associated with mortality rates
as high as 30% [2], and with a 10% annual increase in its
incidence [2], it remains one of the biggest challenges of
modern medicine [3].
The host response to an invading pathogen is one of the
key determinants of patient outcome in sepsis [4]. This
concept has been acknowledged for decades, based on the
limitation of antibiotic therapy for sepsis treatment, and is
supported by increasing knowledge about the cellular and
molecular pathways involved in host:pathogen interaction
[4,5]. Virtually all living beings have developed sensing
mechanisms for rapid detection of invading pathogens,* Correspondence: erich@unicamp.br
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unless otherwise stated.which in humans are represented by pattern-recognition
receptors (PRR). These receptors recognize conserved
motifs in pathogens as well as danger signals that indicate
cellular stress in sterile inflammatory conditions [6,7]. As
expected, receptors and ligands of this sensing system
have been under strong selective pressure during primate
and hominid history [8,9], with pathogens regarded as key
determinants of how these molecules evolved. An illustra-
tion of this concept is provided by the demonstration of
convergent evolution of Toll-like receptor (TLR) genes in
European and Rroma (Gypsy) populations sharing the same
geographic region. Similarities in TLR genes were found be-
tween these two distinct populations which were exposed
to plague in Europe during the Middle Ages, when com-
pared to people from northwest India, which is the geo-
graphic origin of the Rroma population [10]. Because sepsis
severity is mediated by the host response to a pathogen,
it is not surprising that variations in these and other
immune-related genes can influence sepsis severity [11].
However, the cellular processes activated by invading
pathogens during sepsis are not restricted to classical
immune-related genes, but also involve pathways less intui-
tively related to the immune system. Pathways that regulatehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tivation) are two important examples. The former facilitates
access of leukocytes to tissues through diapedesis, contrib-
uting to pathogen clearance. In regard to the latter, discuss-
ing the proximate reasons of why coagulation is activated
in sepsis, and the consequences thereof, are the two main
objectives of this review. The importance of these two
questions lies in the fact that the intensity and regulation of
coagulation activation in sepsis seems to play a major role
in the determination of patient outcome: be it pathogen
clearance (and cure), or the development of secondary tis-
sue damage such as disseminated intravascular coagulation
(DIC) or multiple organ dysfunction [12].
In order to address these important questions from an
evolutionary perspective, we will first discuss some of the
potential selective pressures that molded the hemostatic
system of modern humans. Next, we will confront the
classical view about the role of coagulation activation dur-
ing sepsis with emerging experimental data that could
help us answer the important “why” question about the
evolutionary reasons for coagulation activation during
sepsis. Finally, we will discuss how the views that emerge
from this discussion could influence research on sepsis.
Discussion
Selective pressures molding the hemostatic system
While pathogens are recognized as the main selective pres-
sure on immune-related genes such as TLR and others
[9,13], much less is known about the pressures that influ-
enced the evolution of the hemostatic system. In humans,
the ultimate goal of hemostasis is to keep blood from leav-
ing the intravascular space through acquired breaches in
endothelial lining. This is achieved by a finely regulated
system capable of rapidly responding to the contact of tis-
sue factor (TF), a protein that is normally segregated to the
extravascular space, with coagulation factors present in
plasma. This system is organized in a “cascade” fashion in-
volving platelets, leukocytes, and pro- and anticoagulant
proteins, that act in concert to promote the formation of
clots that seal breaches in the vascular endothelium until
tissue is repaired.
Biochemical and molecular evidence support the idea
that the current organization of the human hemostatic
system evolved more than 450 million years ago [14].
Although little information on the selective pressures
that guided this evolution is available, one can speculate
that increasing complexity of body plan organization may
have been an important factor. Hemostatic systems in in-
vertebrates such as the chelicerate horseshoe crab or in
Drosophila are composed of much fewer genes and pro-
teins than in vertebrates, but they present similarities that
indicate a common origin of at least part of their compo-
nents. For example, clot stability depends on the action of
a transglutaminase that appears to contribute to clottingin all invertebrates, and is homologous to human factor
XIIIa [15]. In animals with more complex body plan
organization, constraints on the diffusion of oxygen and
other vital molecules, as well as compartmentalization of
body functions in different organs, required the develop-
ment of closed circulatory systems, with organ-specific ad-
aptations of vascular bed anatomy and physiology. This
complexity is based on significant heterogeneity of endo-
thelial cell phenotype throughout the vascular tree [16,17]
and is also associated with variations in hemostatic func-
tion between arteries and veins and even within venous
and arterial beds. Organ-specific variations of hemostasis
are well illustrated by clinical differences in the expression
of thromboembolic diseases in different organs [18].
In addition to adaptations to increasingly complex cir-
culatory systems, the close association between hemostasis
and the innate immune response is another factor that in-
fluenced the evolution of the human hemostatic system.
Evidence that hemostasis and inflammation evolved from
a single-triggered mechanism can be traced back more
than 450 million years, based on studies with the horse-
shoe crab (Limulus polyphemus) [19]. Trauma to the exo-
skeleton is a major threat to these invertebrates that
possess a rapid cell-based cascade-like response sys-
tem, able to form an extracellular clot in the event of
any breach to their integument. Since these ancient eu-
karyotes live around ocean waters, evolution selected a
system triggered by minimum concentrations of bacterial
endotoxin, present in Cyanobacteria (blue-green algae) for
more than 2 billion years [20]. Interestingly, the extreme
sensitivity of this system is the basis of the laboratory assay
used to detect endotoxin contamination, which relies on
proteins originated from these invertebrates. Horseshoe
crabs do not possess a circulatory system, and the same
endotoxin-triggered system protects these animals from
both infection and loss of the internal milieu after injury.
In humans, more complex and independent systems exist
for the protection against pathogen invasion and bleeding.
Nevertheless, the sharing of common initiators (such as
endotoxin), as well as the overlap between several path-
ways, indicate the close association between the evolution
of hemostasis and of the immune system during the last
450 million years.
Infectious diseases such as smallpox, bubonic plague,
and malaria are recognized as important selective pres-
sures acting upon the immune system genes in the last
10,000 to 20,000 years [8,21]. However, different selective
pressures must have been relevant to innate immunity
and hemostasis evolution in the remaining 2.5 million
years of Homo evolution [22]. During this long period,
much lower population densities and the nomadic habits
of hunter-gatherers did not allow the same patterns of
pathogen spread observed in post-agricultural societies, so
that trauma, and not contagious infectious disease, was
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observations, a comprehensive necropsy program performed
in a national park in Tanzania identified trauma, rather than
infection, as the main cause of death among chimpanzees in
the wild [23]. Similarly, predation-associated injuries were
identified as a key selective pressure among anthropoid pri-
mates [24]. In an environment in which trauma caused by
conflict or outdoor activities had to be dealt with without
the aid of modern healthcare, a quick-responding and highly
effective hemostatic system was most likely under a strong
positive selection pressure. Moreover, in the absence of basic
hygiene knowledge and antibiotics, it is easy to picture the
importance of hemostasis as part of the innate immune
system, whereby fibrin, platelet and leukocyte-rich clots
contribute to avoid pathogen spread, as stated in the
“hemostatic containment” hypothesis [25].
In this context, any trait that optimized hemostasis and
wound repair without increasing the risk of thrombosis
must have been beneficial in evolutionary terms. Given the
very low prevalence of modern risk factors for thrombo-
embolic diseases in ancient times, the trade-off equation
between bleeding and thrombosis may have favored the de-
velopment of an extraordinarily effective hemostatic system
for ancient challenges, but one that, when exposed to mod-
ern stimuli such as high-fat diet, smoking, sedentarism, and
ageing, contributes to the high prevalence of thrombo-
embolic diseases [26]. The emergence and fixation of
factor V Leiden in northern Europe about 30,000 years
ago is a good illustration of this concept. Factor V Leiden is
a genetic polymorphism that increases an individual’s
hemostatic capacity, resulting in less bleeding during
delivery. However, when combined with the exogenous
estrogen therapy present in oral contraceptives, it increases
the incidence of venous thromboembolism [27]. The fact
that these selective pressures on the hemostatic system op-
erated for much longer periods than recent epidemics of
plague and smallpox, maybe even before the divergence of
humans from other great apes, may explain why modern
tools used to detect selection signatures in our genome
tend to identify the immune system, and not hemostasis, as
a main target of natural selection. Accordingly, variations
favoring a highly efficient hemostatic system may have been
fixed in our genomes for millions of years, and may be less
conspicuous to these statistical tools. Interestingly, KNG1,
the gene encoding kininogen, which is regarded as one of
the main contacts between hemostasis and inflammation,
was recently shown as a target of long-lasting selective
pressure [28].
Classical view of the role of coagulation activation in sepsis
The recent market withdrawal of recombinant activated
protein C (rhaPC), a natural anticoagulant used in the
treatment of sepsis, represents the last chapter of a story
characterized by serial failures of large-scale clinical trialsdesigned to test the generally accepted assumption that
coagulation activation and microvascular thrombosis were
major determinants of tissue damage in sepsis [29]. The
earliest evidences about the role of coagulation activation
during sepsis included histological demonstration of
microvascular thrombosis in target organs of septic patients
and the progressive decrease in platelet counts and coagula-
tion factor levels in the late stages of sepsis, attributed to a
“consumption coagulopathy”. In the following years, the
bulk of the experimental data indicated that sepsis was
indeed associated with a shift in the hemostatic balance
towards a procoagulant state. The most convincing data
were: (i) the demonstration that tissue factor expression
in circulating leukocytes can be stimulated by pathogens;
(ii) an acquired deficiency of endogenous anticoagulant
proteins such as antithrombin and protein C in sepsis
patients; and (iii) a sustained increase in fibrinolysis
inhibitors such as PAI-1, resulting in hypofibrinolysis
[30]. Together, these data supported the concept that
coagulation activation was at least in part responsible
for the organ failure observed in sepsis. Manipulation
of coagulation in animal models of sepsis provided further
support to this concept, by showing that organ failure and
even mortality could be limited by the blockade of discrete
elements of hemostasis such as tissue factor [31] and
factor VII [32], among others.
Based on this model, ambitious clinical development
programs of recombinant natural anticoagulants (anti-
thrombin, TFPI, and rhaPC) in patients with sepsis were
launched, going all the way to phase 3 trials and, in one
case, market approval. Unfortunately, the benefits of this
strategy could not be confirmed in these trials, although
additional clinical trials and meta-analysis are warranted
before a definite conclusion on this issue can be reached
[33]. Limitations of animal models [34] and in clinical
trial design [29] have both been cited as potential expla-
nations for the dissociation between preclinical and clin-
ical data. We could also contribute to this discussion, by
arguing for a more cautionary view of the long-standing
assumption of a direct cause-and-effect relationship be-
tween coagulation activation and multi-organ failure in
sepsis. In fact, the presence of microvascular throm-
bosis in target organs in sepsis was only demonstrated
in studies with a limited number of patients, which did
not consider the different phases of sepsis in their analysis
[35,36]. More recent autopsy studies confirming these
findings are restricted to very small case series of patients
with fulminant sepsis [37,38]. In addition, although we do
not argue against the presence of some degree of systemic
hypercoagulability in sepsis, a concept supported by the
recent demonstration of sepsis as an independent pre-
dictor of venous and arterial thrombosis [39,40], the
presence of this phenomenon in the early stages of sepsis
has been challenged by data generated using global
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regulation of thrombin generation in the early stages of
sepsis [41,42]. In this context, a reappraisal of old and new
data using an evolutionary medicine framework [43] can
refine our understanding about the ultimate and proxim-
ate causes of hemostasis activation during sepsis.
Why is coagulation activated during sepsis?
The concept that coagulation activation can be beneficial
during infections was suggested several years ago [20]
and is gaining increasing support from high-quality data
generated during the last decade. Excellent reviews about
studies linking coagulation and innate immunity have been
recently published [4,44,45]. Our goal here is to present an
updated summary of these studies, highlighting their inter-
pretation from an evolutionary medicine perspective.
Several studies suggest that coagulation proteins are
necessary for eradication of invading pathogens. It is
now known that tissue factor also triggers coagulation-
independent signaling pathways mediated by protease
activated receptors (PARs) on immune cells [46]. These
PAR-dependent signals evoke pro- and anti-inflammatory
pathways that regulate migration and proliferation of im-
mune cells, angiogenesis, endothelial adhesion, and several
other components of the host response to an infection
[47,48]. PAR-dependent pathways are also activated by
other components of hemostasis such as activated protein
C, factor Xa, and thrombin [46], increasing the list of
coagulation factors that regulate immune function.
The contact system, formerly known as the initiator of
the intrinsic pathway of coagulation, is also involved in
the host response to pathogens. Kininogen, one of the
elements of the contact system, is now recognized as
an important source of antimicrobial peptides released
upon the recognition of several microorganisms by this pro-
tein [49]. Of note, a study looking for genomic signatures of
positive selection has recently shown that kininogen has
been under strong selective pressure during evolution [28].
Other components of hemostasis, such as coagulation fac-
tors II, X, and fibrinogen, have also been shown to release
antimicrobial peptides, not necessarily involved with blood
clotting (reviewed in [44]).
Another mechanism by which coagulation activation
contributes to pathogen clearance is by forming a physical
barrier that circumscribes infection foci, thereby facilitating
pathogen clearance by immune cells. This “containment
hypothesis” [25] is now supported by several lines of evi-
dence indicating that down-regulation of different compo-
nents of hemostasis (such as fibrin and platelets) hampers
pathogen clearance (Table 1). A convincing demonstration
that fibrin can be protective during infections comes from a
study with fibrinogen-deficient mice, which presented in-
creased mortality and enhanced bacterial growth in a model
of Listeria monocytogenes infection. The role of fibrinformation in the protective effect was confirmed by the
reproduction of these results in mice treated with warfarin,
an anticoagulant that down-regulates fibrin formation by
an alternative mechanism [50]. A similar strategy confirmed
the role of thrombin generation and fibrin formation in
Yersinia enterocolitica infection [51]. Impaired pathogen
clearance in fibrinogen-deficient mice was also suggested in
a study using a group A streptococcal infection model [52].
Factor XIII, regarded as the most evolutionary conserved
coagulation factor [53], also seems to be important for
pathogen clearance, as suggested by an elegant study show-
ing that Streptococcus pyogenes are immobilized and killed
inside fibrin clots, in a factor XIII-dependent fashion [15].
The fibrinolytic system, which regulates hemostasis func-
tion by the degradation of fibrin thrombi when they are no
longer necessary, also seems to be involved in pathogen
clearance. It has been known for several years that sepsis is
associated with impaired fibrinolysis, attributed to a brisk
rise of a fibrinolysis inhibitor (PAI-1) in plasma [54,55].
While for several years this hypofibrinolytic state was
viewed as one of the causes of microvascular thrombosis
and tissue damage, an alternative explanation would be
that by shutting down fibrinolysis, the host could limit the
spread of invading pathogens by more resistant fibrin clots.
Studies with genetically modified mice support the latter
explanation. Accordingly, mice with tissue-type plasmino-
gen activator deficiency, which results in impaired fibrin-
olysis, presented lower bacterial growth in the primary site
of infection (lungs) in a murine model of Gram-negative
sepsis [56]. In line with this observation, deficiencies of fi-
brinolysis inhibitors PAI-1 [57,58] and α2-antiplasmin [59],
both of which are associated with increased fibrinolytic
activity, resulted in impairment of pathogen clearance
in models of bacterial and viral infections. Another very
significant evolutionary clue comes from the several ex-
amples of pathogen virulence factors based on proteases
that degrade fibrin clots [60], of which streptokinase from
Streptococcus pyogenes [61] and a plasminogen activator
from Yersinia pestis are only the most famous examples
[62,63].
Low platelet counts have long been recognized as an im-
portant prognostic factor in sepsis, based on the assump-
tion that they were a biomarker of sepsis severity. In this
regard, we recently demonstrated that platelet turnover,
measured by the immature platelet fraction, correlates
with sepsis severity [64]. However, recent studies indicate
that platelets are in fact important players in host defense.
Wong et al. demonstrated that platelets interact with
Kupffer cells to encase blood-borne pathogens in the
liver [65]. In another interesting study, antibody-induced
thrombocytopenia resulted in impaired survival and in a
proportional increase in bacterial growth in a model of
pneumonia-derived sepsis [66]. The now widely recognized
participation of neutrophil extracellular traps (NETs) in
Table 1 Effect of coagulation factor deficiencies in animal models of sepsis
Model (genetic alteration) Effect on hemostasis* Sepsis/infection model Effect on pathogen clearance/sepsis severity
EPCR deficiency ↑ Pneumococcal sepsis ↓ bacterial dissemination [81]
Melioidosis** Unaltered [82]
Endotoxemia ↑ mortality [83]
α2-antiplasmin deficiency ↓ Melioidosis** ↑ mortality, ↑ bacterial dissemination [59]
Overexpression of EPCR ↓ Pneumococcal sepsis ↑ bacterial dissemination [81]
Melioidosis** ↑ bacterial dissemination [82]
t-PA deficiency ↑ Melioidosis** ↓ mortality, ↓ bacterial dissemination [56]
Septic peritonitis ↑ mortality, ↑ bacterial dissemination [84]
Factor XI deficiency ↓ Y. enterocolitica (ip) Unaltered [51]
Peritoneal sepsis ↓ mortality [71]
Listeriosis ↓ mortality, ↓ bacterial dissemination [70]
Factor VIII deficiency ↓ Endotoxemia Unaltered [85]
E. coli (ip) ↑ bacterial growth, ↔ survival [86]
Factor IX deficiency ↓ Endotoxemia Unaltered [85]
PAI-1 deficiency ↓ Melioidosis** ↑ mortality, ↑ bacterial dissemination [57]
H. influenza infection ↑ bacterial dissemination [58]
Klebsiella pneumonia ↑ mortality, ↑ bacterial dissemination [87]
Fibrinogen deficiency ↓ Y. enterocolitica (ip) ↑ mortality, ↑ bacterial dissemination [51]
Group A streptococci ↑ mortality [52]
Listeriosis ↑ mortality, ↑ bacterial dissemination [50]
Factor V deficiency ↓ Group A streptococci ↑ mortality [52]
Tissue factor deficiency ↓ S. aureus sepsis Unaltered [72]
Y. enterocolitica (ip) ↑ mortality [51]
Endotoxemia ↓ inflammation [88]
Endotoxemia ↓ mortality, ↓ inflammation [31]
PAI-1 + TAFI double deficiency ↓ Y. enterocolitica (ip) ↑ mortality [51]
Factor II deficiency ↓ S. aureus sepsis ↓ mortality [72]
Factor XIII deficiency ↓ S. aureus sepsis Unaltered [72]
S. pyogenes (skin) ↑ bacterial dissemination [15]
Protein C deficiency (het) ↑ Endotoxemia ↑ mortality [89]
TAFI deficiency ↓ E. coli (ip) Transient ↑ bacterial outgrowth [90]
Factor VII deficiency ↓ Endotoxemia ↓ mortality, ↓ inflammation [32]
Factor V leiden ↑ Septic peritonitis Unaltered [91]
Endotoxemia ↓ mortality [76]***
*The global effect of each genetic deficiency on hemostasis was defined based on current knowledge about hemostatic mechanisms. **Respiratory sepsis by
intranasal instillation of Gram-negative Burkholderia pseudomallei. ***Lower mortality observed only in heterozygous mice. EPCR: endothelial protein C receptor.
t-PA: tissue-type plasminogen activator; PAI-1: plasminogen activator inhibitor-1; TAFI: thrombin-activatable fibrinolysis inhibitor; ip: intraperitoneal; het: heterozygous.
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in NET formation [69] provide another link between
hemostasis and innate immunity [45].
In spite of all these evidences, one should bear in mind
the complexity of the interactions between hemostasis, in-
nate immunity, and pathogens. For yet unknown reasons,
factor XI deficiency in mice, which is also associated with
reduced fibrin formation, has been consistently shown toimprove, rather than hamper, host response in different
models of infection [70,71]. Survival advantage observed
in studies with coagulation factor-deficient mice are not
always consistently observed when different models of in-
fection are used [72]. And in some settings, the so-called
arms race between pathogen and host seems to have
turned fibrin as an asset, rather than a limitation for some
pathogens [72]. Indeed, this complexity is well illustrated
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thrombin generation/clot strength in sepsis outcome in
different animal models (Table 1).
Clinical data also contributed to the idea that some level
of coagulation activation could be beneficial to pathogen
clearance, in that initial studies suggesting that coagula-
tion inhibition could limit tissue damage during sepsisFigure 1 Potential consequences of coagulation activation during sep
mechanisms that contribute to pathogen clearance such as endothelial act
activation is part of this stereotyped response. During sepsis, increased tissue
and hypofibrinolysis result in increased thrombin generation and clot formati
clearance are depicted in panel A and include the release of antimicrobial pe
and limitation of pathogen spread by fibrin-mediated hemostatic containmen
microvascular thrombosis and hypoxia, thereby contributing to tissue damag
activation turns from a beneficial to a detrimental process would allow more
between hemostasis and innate immune response. PAI-1: plasminogen awere not confirmed in phase 3 clinical trials of anticoagu-
lant agents for these patients [73-75]. The impact of factor
V Leiden (FVL), a procoagulant variant of coagulation fac-
tor V, in sepsis mortality is also worth discussing. When
analyzed in the population of a large phase 3 sepsis study,
carriers of FVL presented asignificantly lower 28-day mor-
tality than non-carriers [76]. Although this data could notsis. Recognition of invading pathogens by innate immunity triggers
ivation and recruitment of immune cells to infection sites. Coagulation
factor expression, down-regulation of natural anticoagulant pathways,
on. The beneficial consequences of coagulation activation for pathogen
ptides from the proteolysis of several proteins of the coagulation cascade,
t. However, deregulated coagulation activation could also contribute to
e in sepsis. The precise identification of the moment when coagulation
rational therapeutic approaches for sepsis, preserving the ancient link
ctivator inhibitor-1.
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least challenges the concept of a detrimental effect of
coagulation activation during sepsis.
While the laboratory and clinical evidence presented so
far point to a beneficial role of coagulation activation dur-
ing sepsis, new evidence supporting the classical paradigm
that coagulation activation can contribute to tissue dam-
age in sepsis has also been published. In vivo microvascu-
lar imaging studies demonstrated disturbances of tissue
perfusion in patients with sepsis, which could be reverted
by the use of the anticoagulant activated protein C [77,78].
In addition, the negative results of randomized clinical tri-
als of anticoagulant agents in sepsis have been challenged
by recent systematic reviews and clinical trials [79,80],
suggesting a beneficial effect of this treatment strategy in
subgroups of patients with sepsis. If confirmed (in ongoing
clinical trials and in larger meta-analysis [33]), these results
point to the existence of a threshold above which coagula-
tion activation becomes detrimental during sepsis.
Summary
Ultimate causes of coagulation activation in sepsis and
implications for future research
Together, these data suggest that coagulation activation is
an important component of the overall response against
invading pathogens, and that eradication of invading path-
ogens could be considered the ultimate cause of coagula-
tion activation during infection and sepsis. From this point
of view, one can understand why several individual com-
partments of hemostasis are tuned towards the generation
of increased amounts of thrombin during sepsis, based on
the importance of fibrin and platelets in the host response
to infection. The analysis of coagulation activation during
sepsis from this evolutionary medicine perspective could
also contribute to the explanation of why the use of sys-
temic anticoagulants were not beneficial in large-scale trials
in sepsis, highlighting the importance of identifying the
precise moment at which coagulation activation turns from
a beneficial to a detrimental process in sepsis (Figure 1). In
this context, any targeted treatment for sepsis that limits
coagulation activation should be tailored to preserve
the function of a host defense mechanism that seems to
have been around for at least 450 million years.
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